Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Artificial intelligence has been a mainstay of the Radiological Society of North America (RSNA) annual meeting for nearly a decade. Each year brings new developments, reveals new capabilities and algorithms, and furthers the conversation about how these tools can help radiologists provide care.
This year, the conversation began to turn to what steps could come next for AI. Conversations about deployment, consolidation, and U.S. Food & Drug Administration clearance are now the norm as the technology becomes less of a novelty and more of a mainstay.
In this episode of The Reading Room, Diagnostic Imaging speaks with Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, about her reaction to what this year’s conference offered about these tools and what she sees on the horizon in 2021.
For additional RSNA coverage, click here.
Deep Learning Model with DCE-MRI May Help Predict Proliferative Hepatocellular Carcinoma
May 20th 2024Incorporating dynamic contrast-enhanced MRI, a deep learning model demonstrated a 20 percent higher AUC in external validation testing than clinical factors alone and over a 17 percent higher AUC than radiological factors alone in predicting proliferative hepatocellular carcinoma (HCC).
CT Study: AI Algorithm Comparable to Radiologists in Differentiating Small Renal Masses
May 14th 2024An emerging deep learning algorithm had a lower AUC and sensitivity than urological radiologists for differentiating between small renal masses on computed tomography (CT) scans but had a 21 percent higher sensitivity rate than non-urological radiologists, according to new research.
Appealing Prior Authorization Denials: Can it be Effective for Emerging Technologies?
May 14th 2024While radiologists and other providers may be discouraged by insurer denials saying the use of a technological advance is “unproven and investigational,” 82 percent of appeals for prior authorization denials were approved in 2021.